Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDEC-114: Phase I data; Phase I/II

IDPH said that its 24-patient Phase I trial showed that IDEC-114 had

Read the full 120 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE